scholarly journals Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes

2013 ◽  
pp. 435 ◽  
Author(s):  
Mark Stolar ◽  
Steve Chen ◽  
Michael Grimm
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Agonist ◽  
Extended Release ◽  
Agonist Therapy

PO418 PREDICTION OF RESPONSE TO GLP-1 RECEPTOR AGONIST THERAPY IN JAPANESE PATIENTS WITH TYPE 2 DIABETES

2014 ◽  
Vol 106 ◽  
pp. S258-S259
Author(s):  
K. Imai ◽  
T. Tsujimoto ◽  
A. Goto ◽  
M. Goto ◽  
M. Kishimoto ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Agonist ◽  
Japanese Patients ◽  
Agonist Therapy ◽  
Prediction Of Response

scholarly journals Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes

Diabetes Care ◽  
2015 ◽  
pp. dc150258 ◽  
Author(s):  
Angus G. Jones ◽  
Timothy J. McDonald ◽  
Beverley M. Shields ◽  
Anita V. Hill ◽  
Christopher J. Hyde ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Agonist ◽  
Glycemic Response ◽  
Agonist Therapy ◽  
Β Cell

scholarly journals Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes

2014 ◽  
Vol 6 (1) ◽  
pp. 110 ◽  
Author(s):  
Kenjiro Imai ◽  
Tetsuro Tsujimoto ◽  
Atsushi Goto ◽  
Maki Goto ◽  
Miyako Kishimoto ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Agonist ◽  
Japanese Patients ◽  
Agonist Therapy ◽  
Prediction Of Response

scholarly journals The time-varying cardiovascular benefits of glucagon like peptide-1 agonist (GLP-RA)therapy in patients with type 2 diabetes mellitus: A meta-analysis of multinational randomized trials

2021 ◽  
Author(s):  
Salil Deo ◽  
◽  
David McAllister ◽  
Naveed Sattar ◽  
Jill Pell
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Receptor Agonist ◽  
Meta Analysis ◽  
Agonist Therapy ◽  
Number Of Patients ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Review question / Objective: P - patients with type 2 diabetes melllitus already receiving routine medical therapy; I - patients receiving glucagon like peptide 1 receptor agonist (GLP1 receptor agonist) therapy (semaglutide, dulaglutide, liraglutide, exenatide, lixisenatide, efpeglenatide, abiglutide); C - patients receiving standard therapy for diabetes mellitus but not receiving GLP1 agonist therapy; O - composite end point as per invididual trial, cardiovascular mortality, all-cause mortality, myocardial infarction, stoke. Condition being studied: Type 2 diabetes mellitus. Study designs to be included: Randomised controlled trials which enroll a large number of patients (defined as > 500) and are multinational in origin. Studies included will need to have published Kaplan and Meier curves for the end-points presented in the manuscript.

Sign in / Sign up

Export Citation Format

Share Document